Top Markets
#1 Official Trump Official Trump +43.09%
#2 Mubarak Mubarak +39.27%
#3 Melania Meme Melania Meme +38.90%
#4 The Bitcoin Bull The Bitcoin Bull +26.19%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +19.82%
#6 Movement Movement +19.16%
#7 EXOD EXOD +18.93%
#8 Dash Dash +16.89%
#9 Full Moon Full Moon +16.76%
#10 Verge Verge +16.10%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
Boundless Bio, Inc. Boundless Bio, Inc.

Boundless Bio, Inc.

BOLD
Rank in Stocks #23919
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing... Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Share Price
$3.00
Last synced: 2026-08-21
Market Cap
$67.31M
Change (1 day)
3.28%
Change (1 year)
155.98%
Country
US
Trade Boundless Bio, Inc. (BOLD)

Category

Healthcare
P/E ratio for Boundless Bio, Inc. (BOLD)
P/E ratio as of 2026 TTM: 0
According to Boundless Bio, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Boundless Bio, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.